SOHO 2023 | Optimizing conditioning regimens in patients with AML undergoing alloSCT
Edmund Waller, MD, PhD, FACP, Winship Cancer Institute of Emory University, Atlanta, GA, briefly discusses the outcomes of patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation (alloSCT) with a myeloablative conditioning (MAC) regimen versus a reduced intensity conditioning (RIC) regimen. Dr Waller then goes on to discuss strategies to optimize chemotherapy regimens in patients who are unfit for intensive approaches. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Stock ownership in Cambium Oncology
